이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Axonics 미래 성장

Future 기준 확인 4/6

Axonics (는) 각각 연간 54.3% 및 16.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 54.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 3.9% 로 예상됩니다.

주요 정보

50.4%

수익 성장률

52.2%

EPS 성장률

Medical Equipment 수익 성장	17.6%
매출 성장률	16.5%
향후 자기자본 수익률	4.8%
애널리스트 커버리지	Good
마지막 업데이트	19 Sep 2024

최근 미래 성장 업데이트

Recent updates

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19

We're Hopeful That Axonics (NASDAQ:AXNX) Will Use Its Cash Wisely

Sep 15

수익 및 매출 성장 예측

NasdaqGS:AXNX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	634	71	N/A	N/A	8
12/31/2025	538	43	97	N/A	11
12/31/2024	449	10	51	N/A	12
6/30/2024	409	-2	19	26	N/A
3/31/2024	387	-16	-16	-10	N/A
12/31/2023	366	-6	-6	-2	N/A
9/30/2023	343	-12	-1	2	N/A
6/30/2023	320	-32	-9	-7	N/A
3/31/2023	296	-46	9	12	N/A
12/31/2022	274	-60	1	3	N/A
9/30/2022	241	-76	-16	-13	N/A
6/30/2022	217	-77	-22	-20	N/A
3/31/2022	194	-80	-33	-31	N/A
12/31/2021	180	-80	-50	-47	N/A
9/30/2021	162	-76	-71	-69	N/A
6/30/2021	150	-68	-87	-85	N/A
3/31/2021	120	-63	-88	-86	N/A
12/31/2020	112	-55	-87	-84	N/A
9/30/2020	87	-66	-86	-84	N/A
6/30/2020	53	-82	-90	-88	N/A
3/31/2020	39	-81	-95	-94	N/A
12/31/2019	14	-80	-85	-83	N/A
9/30/2019	4	-67	-66	-65	N/A
6/30/2019	3	-49	-50	-49	N/A
3/31/2019	2	-39	-39	-38	N/A
12/31/2018	1	-32	-33	-31	N/A
9/30/2018	0	-28	-29	-27	N/A
6/30/2018	0	-25	-25	-24	N/A
3/31/2018	0	-20	N/A	-21	N/A
12/31/2017	0	-18	N/A	-18	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AXNX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.4% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: AXNX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: AXNX 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: AXNX 의 수익(연간 16.4% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: AXNX 의 수익(연간 16.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AXNX 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 3.9 %).

Axonics 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Consensus estimates of losses per share improve by 37%

Recent updates

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO & Director exercised options to buy US$7.1m worth of stock.

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Consensus estimates of losses per share improve by 37%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President & CFO notifies of intention to sell stock

Now 20% undervalued after recent price drop

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Chief Operating Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$705k worth of stock

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold US$135k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Axonics stock falls 5.6% after Needham downgrades rating

Chief Technology Officer notifies of intention to sell stock

Executive VP exercised options and sold US$551k worth of stock

Chief Medical Officer recently sold US$748k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Axonics Stock Is A Buy Amid Current Capex Cycle

Executive VP notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Axonics prices stock offering of 1.75M shares

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics, Inc. Updates Revenue Guidance for the Year of 2022

Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Independent Director notifies of intention to sell stock

Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2022

Axonics, Inc. Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System